Trinity Biotech Announces European Approval Of Guideline Compliant, Point-Of-Care, High Sensitivity Troponin I Product

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB) today announced it has obtained the CE mark (i.e. European approval) for its Meritas, high sensitivity Troponin I (hsTnI) product. With its unrivalled precision, it is now the only point-of-care product capable of meeting all of the guidelines stipulated by the world's leading cardiac organisations for detection of heart attacks.

Help employers find you! Check out all the jobs and post your resume.

Back to news